Daclatasvir and Sofosbuvir with Ribavirin for 24 Weeks in Chronic Hepatitis C Genotype-3-Infected Patients with Cirrhosis: A Phase III Study (ALLY-3C)

  title={Daclatasvir and Sofosbuvir with Ribavirin for 24 Weeks in Chronic Hepatitis C Genotype-3-Infected Patients with Cirrhosis: A Phase III Study (ALLY-3C)},
  author={Fred Poordad and Mitchell L. Shiffman and Wayne Ghesquiere and Alexander Wong and Gregory Huhn and Florence Wong and Alnoor Ramji and Stephen D Shafran and Fiona Mcphee and Rong Yang and Stephanie Noviello and Misti Linaberry},
  journal={Antiviral Therapy},
  pages={35 - 44}
Background Optimal treatment for patients with HCV genotype-3 infection and liver cirrhosis remains a medical priority. Daclatasvir+sofosbuvir and ribavirin is a recommended option for such patients, but clinical trial data are lacking for treatment >16 weeks. Methods This was a single-arm, Phase III study of daclatasvir+sofosbuvir+ribavirin for 24 weeks in patients with compensated cirrhosis and HCV genotype-3 infection. The primary end point was sustained virological response at post… 

Figures and Tables from this paper

Effect of adding daclatasvir in sofosbuvir-based therapy in genotype 3 hepatitis C: real-world experience in Pakistan

In patients with chronic hepatitis C genotype 3, SOF/RBV and SOf/DCV±RBV have similar sustained viral response, and patients with liver cirrhosis and past treatment experience have suboptimal response in Pakistan.

Efficacy and Tolerability of Daclatasvir/Sofosbuvir (Datex) in Patients with HIV-HCV Co-infection

Assessment of the tolerability and risk factors, sustained virologic response at 12 weeks after the end of treatment (SVR12), safety, and serum CD4 count was performed in patients with HIV-HCV coinfection in the real-life setting in Iran found the HCV treatment regimen was well-tolerated.

Efficacy and Tolerability of Daclatasvir/Sofosbuvir (Datex) in Patients with HIV-HCV Co-infection

The study showed excellent tolerability and efficacy of DCV/SOF±RBV in HIV-HCV co-infected patients with or without cirrhosis, and 15.9% of patients experienced adverse events (AEs), including anorexia, nausea, diarrhea, palpitations, and anxiety.

Efficacy and Safety of Sofosbuvir-based Regimens in Hepatitis C Patients With Decompensated Cirrhosis: A Systematic Review and Meta-analysis

Decompensated cirrhotic patients with hepatitis C (HCV) are often under-represented in clinical trials, and pooled data on the efficacy and safety of sofosbuvir (SOF)-based regimens in these patients are evaluated, finding that 12 weeks of SOF/velpatasvir without ribavirin is the preferred therapy.

Developments in the treatment of HCV genotype 3 infection

  • F. Mcphee
  • Medicine, Biology
    Expert review of anti-infective therapy
  • 2019
An overview of the evolution of therapies against GT3 since the approval of the first immunomodulatory agent nearly 30 years ago is provided and an interferon-based therapy may still be beneficial in select patient populations with high-level multiple DAA-resistant substitutions.

Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics

The univariate analysis demonstrated the significantly lower sustained virologic response in males, in patients with baseline HCV RNA ≥ 1,000,000 IU/mL, and among those who failed previous DAA-based therapy.

Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life ‘LIver Network Activity’ (LINA) cohort update results

The effectiveness of DAAs is leading to a shift in patients characteristics with a greater prevalence of younger subjects and persons with mild liver disease, and DAAs provide high efficacy also in harder to treat patients.

Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions

A panel of regional experts in the field of hepatology convened to discuss and provide recommendations on the diagnosis, treatment, and pre-, on-, and posttreatment assessment of chronic HCV infection and to ensure the optimal use of cost-effective antiviral regimens in the region.

A Two-Year Outcome Evaluation of Government-Led Initiative to Upscale Hospital-based Hepatitis C Treatment Using a Standard Two-Drug Regimen in Malaysia

A high degree of real-world effectiveness, safety, and affordability of the standard treatment for HCV infection in public hospitals nationwide is demonstrated, suggesting that such a government-led initiative was reasonable and timely and could be extended to include more public health institutions.

Comparison of three therapeutic regimens for genotype‐3 hepatitis C virus infection in a large real‐life multicentre cohort

  • A. SoriaMarco Fava S. Fagiuoli
  • Medicine, Biology
    Liver international : official journal of the International Association for the Study of the Liver
  • 2020
In the direct‐acting antiviral era, treatment of genotype‐3 HCV (HCV‐GT3) is still challenging. Real‐life comparisons between recommended regimens, sofosbuvir (SOF)+daclatasvir (DAC), SOF/velpatasvir



Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort

DCV+SOF with or without RBV achieved high SVR12 and was well tolerated in a diverse cohort of patients with severe liver disease, including patients with advanced liver disease.

Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection.

Among patients with genotype 3 HCV infection, including a large proportion of treatment-experienced patients with cirrhosis, the combination of sofosbuvir, peginterferon, and ribavirin for 12 weeks produces high rates of SVR.

All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study

A 12‐week regimen of DCV plus SOF achieved SVR12 in 96% of patients with genotype 3 infection without cirrhosis and was well tolerated; there were no adverse events leading to discontinuation and only 1 serious AE on‐treatment, which was unrelated to study medications.

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence

High SVR rates across multiple HCV genotypes were achieved by patients with post‐liver transplantation recurrence or advanced cirrhosis and the pan‐genotypic combination of daclatasvir, sofosbuvir, and ribavirin was safe and well tolerated.

Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial

Patients with hepatitis C virus genotype 3 infection with prior treatment experience and/or compensated cirrhosis achieved high SVR12 rates following 12 or 16 weeks of treatment with G/P, and the regimen was well tolerated.

Daclatasvir plus Sofosbuvir, with or without Ribavirin, in Real-World Patients with HIV–HCV Coinfection and Advanced Liver Disease

DCV+SOF, with or without RBV, showed high SVR12 rates and was well tolerated in this real-world cohort of HIV-HCV-coinfected patients with very advanced liver disease.

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.

Among patients with HCV genotype 2 or 3 with or without previous treatment, including those with compensated cirrhosis, 12 weeks of treatment with sofosbuvir-velpatasvir resulted in rates of sustained virologic response that were superior to those with standard treatment withSofosBuvir-ribavirin.

Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

Therapy with sofosbuvir-ribavirin for 12 weeks in patients with hepatitis C virus genotype 2 infection and for 24 weeks in Patients with HCV genotype 3 infection resulted in high rates of sustained virologic response.

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

Among previously untreated HIV-HCV coinfected patients receiving daclatasvir plus sofosbuvir for HCV infection, the rate of sustained virologic response across all genotypes was 97.3% after 12 weeks of treatment and 76.0% after 8 weeks, respectively.

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

Sofosbuvir‐velpatasvir‐voxilaprevir taken for 12 weeks provided high rates of sustained virologic response among patients across HCV genotypes in whom treatment with a DAA regimen had previously failed.